Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The term Other mRNAs with partial complementarity to ESOC1 siRNA seed region refers to a collection of non-target messenger RNA transcripts that are inadvertently silenced by small interfering RNAs (siRNAs) designed to target the ESOC1 gene (also known as DEPP1 or C10orf10). This phenomenon occurs because the seed region of an siRNA (nucleotides 2-8) can bind to the 3' untranslated regions (UTRs) of various mRNAs with partial complementarity, mimicking the regulatory mechanism of endogenous microRNAs [Birmingham, A., et al. (2006). Nature Methods, 3(3), 199-204]. ESOC1 is a protein primarily involved in the regulation of autophagy, response to oxidative stress, and hypoxia-induced pathways [UniProt Q96HI4]. When siRNAs are employed to study ESOC1 function, the unintended downregulation of these off-target mRNAs can lead to experimental artifacts or cellular toxicity, making it difficult to attribute observed phenotypes solely to ESOC1 knockdown. In the context of drug development, these off-targets represent a significant safety concern and a hurdle for the specificity of RNA interference (RNAi) therapeutics. Identifying and minimizing these interactions is essential for the design of high-specificity siRNA molecules and the accurate interpretation of biological data.
Seed-mediated sequence-specific degradation or translational inhibition of non-target mRNAs via the RNA-induced silencing complex (RISC) [Jackson, A. L., et al. (2003). Nature Biotechnology, 21(6), 635-637].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other mRNAs with partial complementarity to ESOC1 siRNA seed region (ESOC1 siRNA off-targets).